Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of MW151 Administered With Whole-brain Radiotherapy in Patients With Intracranial Metastases

NCT05417282 is registered in ClinicalTrials.gov with ImmunoChem Therapeutics, LLC as lead sponsor.

NCT NCT05417282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05417282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of MW151 Administered With Whole-brain Radiotherapy in Patients With Intracranial Metastases
Lead sponsor
ImmunoChem Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2022
Completion date
July 31, 2025
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction, cognitive disorder